Pulmonary Rehabilitation in Interstitial Lung Diseases
Phase 4
Completed
- Conditions
- Interstitial Lung Disease
- Interventions
- Other: Pulmonary Rehabilitation
- Registration Number
- NCT00882817
- Lead Sponsor
- KU Leuven
- Brief Summary
Treatment in interstitial lung diseases (ILD) is frequently ineffective. Pulmonary rehabilitation (PR) is an excellent therapeutic option in another chronic lung diseases such as chronic obstructive pulmonary disease (COPD). This prospective randomized controlled study aims to evaluate the short and long-term effects of PR in patients with ILD. For this purpose, 60 ILD patients will be randomly assigned to a PR or a control group.
The investigators hypothesize that PR will improve exercise capacity, increase muscle force, reduce dyspnea and improve quality of life and daily life activities in ILD patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Diagnosis of interstitial lung disease according to internationally established criteria
- Dyspnea on exertion
- Stable medical therapy
- Stable clinical condition at inclusion, with no infection or exacerbation in the previous 4 weeks
Exclusion Criteria
- Co-morbidities that do not allow exercise training (unstable angina, recent myocardial infarction or cerebrovascular accident, active cancer, severe orthopedic disorders).
- Life expectancy below 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Pulmonary Rehabilitation Pulmonary Rehabilitation
- Primary Outcome Measures
Name Time Method changes in six minute walking distance after 6 months 6 months primary outcome of rehabilitation programm
- Secondary Outcome Measures
Name Time Method Changes in dyspnea and quality of life scores (MMRC, CRDQ, SGRQ), 3-6-12 months Change in peripheral and respiratory muscle force 3-6-12 months Change in maximal exercise capacity 3-6-12 months Change in daily physical activity measured by Sensewear armband 3-6-12 months Changes in pulmonary function and blood gases at rest 3-6-12 months Change number of disease-related hospitalizations and survival 3-6-12 months Change in functional exercise capacity measured by the 6 minute walking distance 12 months To evaluate feasibility and safety of pulmonary rehabilitation in interstitial lung disease 6 months Changes in six minute walking distance at 3, 12 months
Trial Locations
- Locations (1)
Katholieke Universiteit Leuven
🇧🇪Leuven, Flanders, Belgium